Inclusion Body Myositis News and Research RSS Feed - Inclusion Body Myositis News and Research

New antibody could boost strength, muscle mass in patients with cancer and other diseases

New antibody could boost strength, muscle mass in patients with cancer and other diseases

A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease, sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology. [More]

FDA grants Orphan Drug designation to Milo Biotechnology's AAV1-FS344 inhibitor

Milo Biotechnology today announced its AAV1-FS344 has been granted Orphan Drug designation from the FDA's Office of Orphan Products Development for treatment of Becker and Duchenne muscular dystrophy. AAV1-FS344 is a gene therapy-delivered myostatin inhibitor that increases muscle strength. [More]
Columbus hospital receives PPMD grant to conduct clinical testing for Duchenne

Columbus hospital receives PPMD grant to conduct clinical testing for Duchenne

Parent Project Muscular Dystrophy, the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), will award a $600,000 grant to Nationwide Children's Hospital in Columbus, Ohio to conduct clinical testing of a promising gene therapy technique for muscle disease. [More]

Gene delivery strategy to help improve muscle mass in patients with degenerative muscle disorders

Severe weakness of the quadriceps is a defining feature of several neuromuscular disorders. Researchers at Nationwide Children's Hospital have shown that a gene delivery strategy that produces follistatin - a naturally occurring protein that inhibits myostatin, a growth factor expressed specifically in skeletal muscle - directly to the quadriceps of non-human primates results in long-term gene expression with muscle enhancing effects, including larger muscles with greater strength. [More]
Alzheimer's vaccine slows progression of inclusion body myositis

Alzheimer's vaccine slows progression of inclusion body myositis

A potential vaccine for Alzheimer's disease also has been shown in mice to slow the weakening of muscles associated with inclusion body myositis, a disorder that affects the elderly. [More]
Gene therapy for muscular dystrophy a step closer

Gene therapy for muscular dystrophy a step closer

Researchers have cleared a safety hurdle in efforts to develop a gene therapy for a form of muscular dystrophy that disables patients by gradually weakening muscles near the hips and shoulders. [More]
Lithium chloride slows development of inclusion body myositis

Lithium chloride slows development of inclusion body myositis

A new UC Irvine study finds that lithium chloride, a drug used to treat bipolar disorder, can slow the development of inclusion body myositis, a skeletal muscle disease that affects the elderly. [More]

Massive microRNA scan uncovers leads to treating muscle degeneration

Researchers have discovered the first microRNAs - tiny bits of code that regulate gene activity - linked to each of 10 major degenerative muscular disorders, opening doors to new treatments and a better biological understanding of these debilitating, poorly understood, often untreatable diseases. [More]
Myositis featured on Discovery Channel

Myositis featured on Discovery Channel

LaShan Davis, featured this week on The Discovery Channel's “Mystery Diagnosis” spent three 10-hour days filming the segment and reliving the terrifying time she spent waiting for her “mystery disease” to be diagnosed. [More]

A trial of beta-interferon-1a in inclusion-body myositis has failed to find benefit from the drug in this disease

A trial of beta-interferon-1a in inclusion-body myositis (IBM) has failed to find benefit from the drug in this disease. Beta-interferons counteract some of the activities of the immune system, which some experts believe is misguided in IBM. [More]